Systemic inflammation and B cell indices predict rituximab responses in membranous nephropathy
B lymphocyte levels constitute a robust predictive biomarker for assessing short-term therapeutic response in patients with MN receiving RTX therapy. Furthermore, SIRI emerges as a valuable prognostic indicator capable of predicting both short-term efficacy and long-term renal outcomes. These findings suggest that concurrent monitoring of B lymphocyte levels and SIRI values warrants integration into standardized monitoring frameworks within clinical management protocols.
Authors
- Bo Zhang (ORCID: https://orcid.org/0000-0002-8903-2089)
- Yuyu Ye
- Ming Zeng (ORCID: https://orcid.org/0000-0002-4294-2077)
- Qian Zhou (ORCID: https://orcid.org/0000-0001-7890-0664)
- Huijuan Mao (ORCID: https://orcid.org/0000-0003-4542-6390)
- Hujia Hua
- Yanggang Yuan (ORCID: https://orcid.org/0000-0003-2764-9486)
- Changying Xing (ORCID: https://orcid.org/0000-0002-9412-2919)
- Chengning Zhang (ORCID: https://orcid.org/0000-0003-1040-8934)
- Suyan Duan (ORCID: https://orcid.org/0009-0003-6529-3801)
Institutions
- Nanjing Medical University (CN)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1093/ckj/sfaf396
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- Nanjing Medical University
- Priority Academic Program Development of Jiangsu Higher Education Institutions